Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
26,100
Total Claims
$2.0M
Drug Cost
710
Beneficiaries
$2,748
Cost/Patient
Risk Score Breakdown 36/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,124 General Surgery providers
-99%
Opioid rate vs peers
0.4% vs 30.2% avg
+987%
Cost per patient vs peers
$2,748 vs $253 avg
+267%
Brand preference vs peers
18.3% vs 5.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 987% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.4%
Opioid Rate
106
Opioid Claims
$2,944
Opioid Cost
10.4%
Long-Acting Rate
Brand vs Generic
Brand: 4,773 claims · $1.3M
Generic: 21,311 claims · $680K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,019 | $305K |
| Dulaglutide | 190 | $134K |
| Pimavanserin Tartrate | 44 | $101K |
| Fingolimod Hcl | 15 | $88K |
| Rivaroxaban | 234 | $74K |
| Collagenase Clostridium Hist. | 23 | $64K |
| Insulin Glargine,hum.Rec.Anlog | 177 | $38K |
| Mirabegron | 137 | $33K |
| Fluticasone/Umeclidin/Vilanter | 48 | $25K |
| Divalproex Sodium | 464 | $25K |
| Rifaximin | 14 | $23K |
| Atorvastatin Calcium | 1,271 | $23K |
| Sitagliptin Phosphate | 57 | $23K |
| Empagliflozin | 61 | $19K |
| Linaclotide | 35 | $18K |
Prescribing Profile
Patient Profile
77
Avg Age
45%
Female
2.81
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About